Press releasePRNewswire
Citius Pharmaceuticals
CTXR · NASDAQ
$0.4175−$0.0103 (−2.41%)TodayMarket closed ·
Prev close $0.4278
Latest news
- Press releasePRNewswire
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
- Press releasePRNewswire
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
- Press releasePRNewswire
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
- Press releasePRNewswire
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releasePRNewswire
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
- Press releasePRNewswire
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
- NewsAlex Perry
What's Behind The Drop In Citius Pharmaceuticals?
- Press releasePRNewswire
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releasePRNewswire
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
- Press releasePRNewswire
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
- Press releasePRNewswire
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releasePRNewswire
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
- News
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Press releasePRNewswire
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
- Press releasePRNewswire
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
- NewsAvi Kapoor
Gold Edges Lower; Omeros Shares Jump
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Dow Gains Over 100 Points; US Jobless Claims Decline
- NewsRishabh Mishra
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)
- NewsMohd Haider
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
- Press releasePRNewswire
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.